| Literature DB >> 35639237 |
Kevin Verhoeff1,2, Nerea Cuesta-Gomez1,2, Ila Jasra1,2, Braulio Marfil-Garza3, Nidheesh Dadheech1,2, A M James Shapiro4,5,6.
Abstract
Islet transplantation is a highly effective treatment for select patients with type 1 diabetes. Unfortunately, current use is limited to those with brittle disease due to donor limitations and immunosuppression requirements. Discovery of factors for induction of pluripotent stem cells from adult somatic cells into a malleable state has reinvigorated the possibility of autologous-based regenerative cell therapies. Similarly, recent progress in allogeneic human embryonic stem cell islet products is showing early success in clinical trials. Describing safe and standardized differentiation protocols with clear pathways to optimize yield and minimize off-target growth is needed to efficiently move the field forward. This review discusses current islet differentiation protocols with a detailed break-down of differentiation stages to guide step-wise controlled generation of functional islet products.Entities:
Keywords: Diabetes; Differentiation; Inducible pluripotent stem cells; Islet cell transplant
Year: 2022 PMID： 35639237 DOI： 10.1007/s12015-022-10391-3
Source DB: PubMed Journal: Stem Cell Rev Rep ISSN： 2629-3277 Impact factor: 6.692